Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
ARUP Laboratories, |
RCV001515198 | SCV000605523 | benign | not provided | 2023-11-27 | criteria provided, single submitter | clinical testing | |
Medical Genetics Summaries | RCV000664406 | SCV000788338 | drug response | Irinotecan response | 2018-04-04 | criteria provided, single submitter | curation | UGT1A1*36 is not associated with irinotecan toxicity. This variant is associated with increased promoter activity and a reduced risk of neonatal hyperbilirubinemia. |
Labcorp Genetics |
RCV001515198 | SCV001723217 | benign | not provided | 2020-10-19 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001515198 | SCV001937662 | benign | not provided | 2018-07-15 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003965423 | SCV004791887 | benign | UGT1A9-related disorder | 2022-07-11 | no assertion criteria provided | clinical testing | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |